skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
Daewoong Pharmaceutical’s botulinum toxin becomes the first Korea-made Botulinum Toxin to obtain US FDA approval
Date 2019-02-02 Hit 3784
News List
Prev Daewoong’s Hyangnam Plant acquires International Standard ISO 45001 (Safety & Health Management Systems)
Next The clinical findings of Botulinum Toxin manufactured by Daewoong have been published on international journal regarding the comparison with Botox